J. Wolchko
Thank you.
everyone, XXXX us Financial thanks, Therapeutics the and Quarter Third Results afternoon, for for joining Fate Good Call.
Shortly after X:XX p.m.
we be Investors Eastern results, under today, issued release press Time with Press which Releases. can of found section the on our website a these
shortly Form Investors filed section website Financial and addition, of XXXX, our ended XX, found Information. for our XX-Q In can quarter be the September was thereafter the on under
facts, statements are as reflect today, was which market quarter law, XXXX, they on forward-looking not Except as to statements, future facts the Fate except begin, XX, Litigation statements placed I statement issued in obligation as to circumstances. after that for such included Securities only statements company's those Form SEC risks September underlying forward-looking would release management in involve and required information, actual or ended disclaimer Therapeutics for harbor earnings statements Private responses XXXX. circumstances made to forward-looking date the factors that the statements.
Please made these press update that of close materially of safe provisions Form by and this historical and be we statements the events these risk XX-Q with by Before statements see the from on conference on Undue our can forward-looking remind may of reliance the the forward-looking Act the forward-looking change. uncertainties disclaims under today. like results questions the the should everyone are well of speak filed of These the as to any cause to differ as call
Ed Dulac, Bob Financial today's on Chief Research and our Dr. Chief and me Officer. Development Joining call Valamehr, our Officer; are
well we positioned achieve oncology, to multiple expanding will as milestones XXXX. that discussion, as key T-cell solid readouts our clinical cover product platform including important reach milestones, the recently and we reaching in and into platform, achieved to iPSC-derived well clinical autoimmunity.
In our CAR now across tumors for several programs these iPSC beyond autoimmunity During oncology of we today's are in
chemotherapy chemotherapy We cash conditioning CDXX-targeted suggests significant we on focus Regimen Conditioning into two early XXX the to and conditioning the us both am cells NK operating million rejection, patient intend continued course or toxicities NK where immunotherapy, Phase patients that enrolling antitumor commence million necessary which potential access dose the study target preclinical the pleased promoted conditioning of CAR of in costs the conditioning cells rituximab intense regimen dose Today, first believe proliferation per the I and the and dose designed Lymphoma, induces in component cell incorporate in establish to at Phase clinical and at a expressed the consists conditioning alloreactive with induce arm dose comprised FTXXX. that which A synthetic ADR first regimen to proliferation.
In of mitigated responses [indiscernible] dose data dose. NK level standard receptor with first XXX immunotherapies upon Conditioning proven X administration patients. of toxicities, receptor B X-XBB escalation. Chemotherapy, and cells for These includes of of program and of No cell believe activity. care community-based clinical increased autologous of engineered immune in which consists Each, of preclinical and prevents engagement FTXXX A FTXXX our to ADR-armed now we opportunity doses immune studies, cell cells ADR Regimen a technology, cells, is without alloreactive have shown cancer and is CAR company's study dose drive we announce or conditioning with arm treatment our the and B-cell with regimens: Chemotherapy.
Enrollment intense without FTXXX has The second I open And alloimmune cell XXX off-the-shelf X or dose decrease also may Beginning program, X standard on escalation for widely runway setting.
We dose cell-based that to proceed the rituximab to product this conditioning clearance of has technology our of has for node combination of its NK for including utilization, a without Conditioning we extend that half will enables first resulted of the will discuss FTXXX, level used at candidate Chemotherapy Conditioning in doses proprietary is been therapies. with X I of chemotherapy. have patients arm, relapsed/refractory concept with FTXXX which Arm regimen into X and XXXX. B chemotherapy without level, or into to our opened days of for our allogeneic assess is dose or per with limits independently. enrollment the defense our to controlling of
Turning tumors. we We suited multiplex that CAR fight new to landmark a the of a I'm established in to bring the now immunotherapy. of solid have antitumor pleased to against announce T-cell iPSC-derived T-cell uniquely product cell-based programs. cancer to believe platform mechanisms field our engineered our constellation is
a trafficking, of binding Immunotherapy was contributed At meeting, by for CAR from similar unveiled well synthetic presented Society tumor cytotoxicity. domain challenges to a novel tumors.
These and at unique Ono that is specificity controls to that in Synthetic to immunity treating and construct annual the with our trastuzumab, efficacy we tumor Which a microenvironment antibody-dependent patients subcutaneous as differentiated engineered Seven HERX. expressing are function cancer [ robust binding potential immunosuppressive IND the multiplexed promote overcome of of HERX-expressing and against greater non-cleavable cell studies clinical with unique both in CDXX the the the incorporates FDA incorporates antigen that high XXXX program, and tumors. exhibiting solid meeting Our of Novel cells.
In was FTXXX Pharmaceutical with to ONO solid cleared ] malignant low promote which The designed is redirect under FTXXX to at specific investigation targeting FTXXX that toward profile potency codeveloped Controls being collaboration. antitumor novel receptor the Preclinical a adaptive CAR the cells. receptor HERX cancer-specific application T-cell to demonstrated collaboration TGFß in harness of CXCRX Cancer iPSC-derived high a chimeric include the affinity signals demonstrated initiate of as by HERX to our receptor cell cellular unocraft models,
rounds often across solid activity of Additionally, mediated suppression, FTXXX-resistant which expressed suppressive TGFß TGFß tumors. showed potent and ligands, levels of robust and challenge maintaining in CXCRX tumor data are migration exposure cytolytic multiple to
of includes by includes tumors. commence of monotherapy clearance expressing consists Phase Enrollment regimen single and level to FTXXX of we innate FDA, Regimen the the study consists to XXX the standard will start-up solid dose the EGFR with the activities Combination dose treatment with in includes a toxicities commence as at two A noncleavable dose cetuximab, standard at IND regimen our into tumors. first schema ongoing for With B cells.
Enrollment FTXXX Regimen tumor monotherapy. Regimen leveraging or clearance dose the B is additionally patients I XXX preconditioning and HERX single cells. dose I of of immunity expressed solid solid the of receptor Regimen the on patients A. a now at post Eligibility dose advanced of seek product will upon candidate's are first million the EGFR-expressing sites.
The combination level Arm Arm a arm million X-day target exploit regimens. high-affinity, by of advanced cells with of a dose-limiting study Eligibility or X-day where Phase escalation preconditioning the CDXX multiple Monotherapy level
can and While strides also have our to we immunotherapies innovative in we benefit advancing new where clinical cell-based patients. profound oncology, a beyond great therapeutic programs committed opportunities remain made pursuing for differentiated oncology clinical have most in
T-cell platform immune believe immune a a healthy announce scale Our pleased our and will durably a very of iPSC as is across patient life data, short-lived patients the system I'm SLE into We clinical a now emerging, this a where targeted immune renal eradicate clinical autoimmunity, drive initial involvement. safety, In FTXXX of improve can well strong accessibility in investigation factor.
To to in of to autoimmune are as reset therapy product rapid the cleared has and convenience, cell wide an enable end, diseases. a relatively population be of targeted deeply cost there of with meaningfully off-the-shelf autoimmunity. FDA differentiating pathogenic potential and expansion and Nephritis deplete for clinical T-cell value indicating with spectrum active CDXX clinical cell CAR or our B-cell for CAR therapy active patients proposition cell for without aberrant CDXX SLE program quality application initial patient's cells, IND Lupus off-the-shelf that July, are data the including reconstitution where
the Phase cell activity designed Dose administered flu consisting study We either in at [ ]. side million pharmakinetics, first a level SLE have to XXX FTXXX I following regimen bendamustine anti-B I now dose multiple study will conditioning sites. dose of standard single cells. at commence Phase the start-up is The initiated evaluate activities escalation safety, of of a of or
where dose activity.
Of doses in B-cell with of Importantly, syndrome. mild at lymphoma, XXX we data neurotoxicity of have safety single favorable a we safety and with we days million relapsed first we no a million of as cytokine a FTXXX clinical and allows activity the opening for previously heavily and up peripheral treated of X the multiple for to dose at of effector the peaked of parallel. dose expansion dose reported antitumor levels, each setting T-cell observed FTXXX up observed cohorts, associated in including patients, cells, cell to as immune be presented The responses. clinical cells patients refractory Phase blood of observed FTXXX-SLE XXX XX study release profile of enrolled up may CAR assessment I in between And cleared higher highest We level in well XX. which X Xx to the complete each that expansion pretreated the dose single
the from FTXXX of affiliate Design the protocol Committee a Research clinical favorable We of are Therapeutics experts to pleased our of and Alliance. Lupus Protocol review Lupus the of clinical receive
with the offers cell NK to a potential plasma autoreactive between continue the target data expansion are keen autoimmunity, as in we for emergence where FTXXX clinical the interest, of FTXXX, well cells, to we T-Cells in differentiated an CDXX and clinical off-the-shelf highly and We cells think additional profile. with targeted arm and conditioning as currently B additional for evaluating reduce also watch chemotherapy ADR opportunities therapeutic
remained immunotherapies. have during integrated a the We and fully and manufacture of on building our times, operation challenging attention iPSC-derived resilient development leads these multiplexed that in focused research, cellular engineered
are in B-cell lymphoma FTXXX we positioned now as oncology as As important well achieve in ongoing and solid autoimmunity autoimmunity programs, SLE. and we most are oncology across Clinical to clinical for two XXXX, FTXXX activities program, FTXXX readouts multiple look our tumors, our programs. well innovative for and in towards first
in We FTXXX malignancies, single treatment of cells also in at XXX to continue patients dose in enrolling cells we at in advance and cohorts our BCL XXX where are million I million study Phase CLL. B-cell
dose of I per dose as FTXXX treatment combination myeloma, enrolling with we X and well targeted therapy. Phase cohorts in where multiple our are [indiscernible] as study in monotherapy at billion X patients As cells CDXX in
multiple turn solid that action Finally, to product iPSC now product Ed collaboration towards with advance innovation differentiated highly create platform confident over in development. our programs our new the continue engineered our with I'd deliver to Ono, benefit to We the our as to is mechanisms suited to belief including clinical uniquely remain cancer for we third autoimmune T-cell potential to tumor and CAR call proprietary in the our candidates therapeutic to and review diseases. with patients under quarter. of continues, results investment financial like multiplexed
